Structural Variation in the 3D Genome

Total Page:16

File Type:pdf, Size:1020Kb

Structural Variation in the 3D Genome REVIEWS TRANSLATIONAL GENETICS Structural variation in the 3D genome Malte Spielmann 1, Darío G. Lupiáñez2 and Stefan Mundlos 3,4* Abstract | Structural and quantitative chromosomal rearrangements, collectively referred to as structural variation (SV), contribute to a large extent to the genetic diversity of the human genome and thus are of high relevance for cancer genetics, rare diseases and evolutionary genetics. Recent studies have shown that SVs can not only affect gene dosage but also modulate basic mechanisms of gene regulation. SVs can alter the copy number of regulatory elements or modify the 3D genome by disrupting higher- order chromatin organization such as topologically associating domains. As a result of these position effects, SVs can influence the expression of genes distant from the SV breakpoints, thereby causing disease. The impact of SVs on the 3D genome and on gene expression regulation has to be considered when interpreting the pathogenic potential of these variant types. Structural variation The application of molecular karyotyping and, more the position and/or function of cis- regulatory elements, (SV). Genetic variation that recently, next- generation sequencing (NGS) has such as promoters and enhancers. Owing to advances in includes all structural and revealed the enormous structural complexity of the 3D genome mapping technologies, it is now becoming quantitative chromosomal human genome1–3. Structural and quantitative chromo- increasingly evident that position effects are the result of rearrangements, that is, deletions and duplications, as somal rearrangements, collectively referred to as much more complex alterations than just changes in the well as copy- number-neutral structural variation (SV), include deletions, duplications, linear genome. Recent findings have shown that posi- aberrations, such as inversions, inversions, insertions and translocations and make tion effects can be understood only by taking the third insertions and translocations. up the majority of varying nucleotides among dimension of chromosomes into account — the folding human genomes4. Unbalanced rearrangements, also of chromatin in the 3D space of the nucleus. known as copy number variation (CNV), alter the dip- In this Review, we first discuss how SVs can rear- loid status of DNA by changing the copy number of range the order and number of genes and regulatory chromosomes or chromosomal regions5, whereas elements, resulting in human disease. We then describe balanced rearrangements such as inversions, recip- in detail how SVs can modify the 3D organization of rocal translocations or copy- number-neutral inser- the genome by disrupting chromatin domains. We tions do not result in loss or gain of genetic material. also describe the phenotypic consequences of genomic Germline SVs ranging from whole- chromosome disorders resulting from reshuffling of non- coding 1Department of Genome abnormalities, such as trisomy 13, 18 or 21, to recur- enhancer sequences and chromatin domain bounda- Sciences, University of rent microdeletion and microduplication syndromes are ries with the aim of presenting possible strategies for Washington, Seattle, 6–10 WA, USA. a common cause of congenital disease , and high the medical interpretation of SVs in the 3D genome. 2Epigenetics and Sex levels of somatic SVs are a key signature of human cancer We do not review the mechanisms underlying chromo- 1,11 Development Group, Berlin genomes . High- throughput sequencing technologies some organization, nor do we discuss methods for SV Institute for Medical Systems have dramatically accelerated the discovery and charac- detection by chromosome conformation capture (3C) or Biology, Max- Delbrück terization of SVs; however, the medical interpretation related technologies; for recent reviews on these topics, Center for Molecular of SVs and the prediction of phenotypic consequences see REFS4,18–22. Medicine, Berlin- Buch, 12 Germany. remain unsatisfactory . Structural variation in disease 3Max Planck Institute for The discovery that SVs can be pathogenic without Molecular Genetics, RG changing coding genome sequences first indicated that Great progress has been made in the detection of single Development & Disease, SVs can have regulatory effects, which were explained by nucleotide variants in health and disease. However, the Berlin, Germany. so-called position effects13,14. Indeed, 98% of the genome is genetic analysis of SV has been limited by technical chal- 4Institute for Medical and non-coding 15, and a large part of the non-coding genome lenges. Although array comparative genomic hybridiza- Human Genetics, Charité is, in one way or another, involved in gene regulation. tion (array CGH) is effectively used in routine clinical Universitätsmedizin Berlin, 5,10 Berlin, Germany. The complexity of assigning function to non- coding diagnostics for the detection of CNVs , this technique *e- mail: mundlos@ regions makes accurate estimates difficult; the fraction has limitations owing to its fairly low resolution, its ina- molgen.mpg.de of the genome implicated in gene regulation has been bility to detect balanced rearrangements and its low effi- 16 17 23 https://doi.org/10.1038/ estimated to be 5% or 80% depending on the study. cacy in mosaic individuals . Whole-genome sequencing s41576-018-0007-0 Nonetheless, SVs have a high probability of affecting (WGS) by short- read technology has the potential to NATURE REVIEWS | GENETICS VOLUME 19 | JULY 2018 | 453 © 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. REVIEWS Copy number variation detect all rearrangements but lacks the ability to detect even within the same data sets, highlights the current (CNV). Genetic variation that breakpoints in repetitive regions, where many break- uncertainty in both the mutation rate of de novo SVs refers only to quantitative points occur24. Long- read sequencing technology, for and their impact on disease. chromosomal rearrangements, example, single molecule real time sequencing or nano- To establish disease- specific SV morbidity maps such as deletions and duplications. pore sequencing, is expected to overcome these problems of the human genome, several large initiatives such as but currently remains too expensive for routine clinical the 100,000 Genomes Project42 and the Deciphering Microdeletion and application25,26. Developmental Disorders (DDD) study43 are evaluat- microduplication syndromes ing the amount of de novo SVs in a variety of patient A group of syndromes that are De novo structural variation cohorts. Equivalent CNV morbidity maps have proved caused by chromosomal microdeletions and One important question in human genetics is how much to be extremely useful for the clinical interpretation of 6,7,10,31 microduplications, which make variation is normally present in the human genome and CNVs . The most comprehensive SV database to up a subset of copy number how much is specific to disease. Using all currently date, the Database of Genomic Variants (DGV) provides variations that are usually available methodologies to define the full spectrum of a catalogue of SVs found in the genomes of control indi- smaller than 5 Mb. Classic 44 examples include the 7q11 human genetic variation, >30,000 SVs can be detected viduals from diverse populations . The current version 27 deletion (Williams–Beuren per human genome . In a clinical diagnostic setting, includes >22,300 genomes. syndrome), the 15q11–15q13 following their identification, each variant needs to be Although de novo SVs are more likely to cause deletion (Prader–Willi and carefully evaluated according to the specific phenotype disease, it should be noted that a considerable num- Angelman syndromes) and and family history of the patient, as well as in terms of ber of recurrent microdeletion syndromes exhibit the 17p11 deletion penetrance (Smith–Magenis syndrome). the gene content and genetic context of the variant, in reduced or high clinical variability. For order to assign pathogenicity to an SV. To differenti- example, only 15% of 15q13.3 microdeletions arise Position effects ate polymorphic from potentially disease- causing SVs, de novo, and they present with a wide range and sever- Effects of structural variation it is essential to validate whether an SV has occurred ity of phenotypes45. Reduced penetrance and high clin- (SV), classically translocations, on the expression of a gene de novo or whether it is inherited, as de novo SVs are ical variability represent key challenges for the medical 10 without any changes to its more frequently associated with disease . Large- scale interpretation of SVs. A possible explanation for reduced coding sequence or promoter studies have established a role for de novo CNVs in the penetrance can be underlying recessive or biallelic inher- region. These effects can also aetiology of many diseases, including intellectual disabil- itance, which was described for thrombocytopenia be observed if a gene is ity28,29, autism spectrum disorders (ASDs)6,30, congenital absent radius syndrome46, for example. inserted into different regions 7 8,9 of the genome or if SVs heart disease , sporadic schizophrenia and congenital 31 connect previously limb malformation . For ASDs, approximately 3.7% Gene dosage unconnected genes and their of affected individuals were found to carry a large The pathogenicity of SVs that disrupt or include cod- regulatory units. In these cases, (>500 kb) de novo CNV, in contrast to only 0.4−0.8% ing sequences is currently interpreted
Recommended publications
  • Prevalence and Incidence of Rare Diseases: Bibliographic Data
    Number 1 | January 2019 Prevalence and incidence of rare diseases: Bibliographic data Prevalence, incidence or number of published cases listed by diseases (in alphabetical order) www.orpha.net www.orphadata.org If a range of national data is available, the average is Methodology calculated to estimate the worldwide or European prevalence or incidence. When a range of data sources is available, the most Orphanet carries out a systematic survey of literature in recent data source that meets a certain number of quality order to estimate the prevalence and incidence of rare criteria is favoured (registries, meta-analyses, diseases. This study aims to collect new data regarding population-based studies, large cohorts studies). point prevalence, birth prevalence and incidence, and to update already published data according to new For congenital diseases, the prevalence is estimated, so scientific studies or other available data. that: Prevalence = birth prevalence x (patient life This data is presented in the following reports published expectancy/general population life expectancy). biannually: When only incidence data is documented, the prevalence is estimated when possible, so that : • Prevalence, incidence or number of published cases listed by diseases (in alphabetical order); Prevalence = incidence x disease mean duration. • Diseases listed by decreasing prevalence, incidence When neither prevalence nor incidence data is available, or number of published cases; which is the case for very rare diseases, the number of cases or families documented in the medical literature is Data collection provided. A number of different sources are used : Limitations of the study • Registries (RARECARE, EUROCAT, etc) ; The prevalence and incidence data presented in this report are only estimations and cannot be considered to • National/international health institutes and agencies be absolutely correct.
    [Show full text]
  • Orphanet Report Series Rare Diseases Collection
    Marche des Maladies Rares – Alliance Maladies Rares Orphanet Report Series Rare Diseases collection DecemberOctober 2013 2009 List of rare diseases and synonyms Listed in alphabetical order www.orpha.net 20102206 Rare diseases listed in alphabetical order ORPHA ORPHA ORPHA Disease name Disease name Disease name Number Number Number 289157 1-alpha-hydroxylase deficiency 309127 3-hydroxyacyl-CoA dehydrogenase 228384 5q14.3 microdeletion syndrome deficiency 293948 1p21.3 microdeletion syndrome 314655 5q31.3 microdeletion syndrome 939 3-hydroxyisobutyric aciduria 1606 1p36 deletion syndrome 228415 5q35 microduplication syndrome 2616 3M syndrome 250989 1q21.1 microdeletion syndrome 96125 6p subtelomeric deletion syndrome 2616 3-M syndrome 250994 1q21.1 microduplication syndrome 251046 6p22 microdeletion syndrome 293843 3MC syndrome 250999 1q41q42 microdeletion syndrome 96125 6p25 microdeletion syndrome 6 3-methylcrotonylglycinuria 250999 1q41-q42 microdeletion syndrome 99135 6-phosphogluconate dehydrogenase 67046 3-methylglutaconic aciduria type 1 deficiency 238769 1q44 microdeletion syndrome 111 3-methylglutaconic aciduria type 2 13 6-pyruvoyl-tetrahydropterin synthase 976 2,8 dihydroxyadenine urolithiasis deficiency 67047 3-methylglutaconic aciduria type 3 869 2A syndrome 75857 6q terminal deletion 67048 3-methylglutaconic aciduria type 4 79154 2-aminoadipic 2-oxoadipic aciduria 171829 6q16 deletion syndrome 66634 3-methylglutaconic aciduria type 5 19 2-hydroxyglutaric acidemia 251056 6q25 microdeletion syndrome 352328 3-methylglutaconic
    [Show full text]
  • Copyrighted Material
    Part 1 General Dermatology GENERAL DERMATOLOGY COPYRIGHTED MATERIAL Handbook of Dermatology: A Practical Manual, Second Edition. Margaret W. Mann and Daniel L. Popkin. © 2020 John Wiley & Sons Ltd. Published 2020 by John Wiley & Sons Ltd. 0004285348.INDD 1 7/31/2019 6:12:02 PM 0004285348.INDD 2 7/31/2019 6:12:02 PM COMMON WORK-UPS, SIGNS, AND MANAGEMENT Dermatologic Differential Algorithm Courtesy of Dr. Neel Patel 1. Is it a rash or growth? AND MANAGEMENT 2. If it is a rash, is it mainly epidermal, dermal, subcutaneous, or a combination? 3. If the rash is epidermal or a combination, try to define the SIGNS, COMMON WORK-UPS, characteristics of the rash. Is it mainly papulosquamous? Papulopustular? Blistering? After defining the characteristics, then think about causes of that type of rash: CITES MVA PITA: Congenital, Infections, Tumor, Endocrinologic, Solar related, Metabolic, Vascular, Allergic, Psychiatric, Latrogenic, Trauma, Autoimmune. When generating the differential, take the history and location of the rash into account. 4. If the rash is dermal or subcutaneous, then think of cells and substances that infiltrate and associated diseases (histiocytes, lymphocytes, mast cells, neutrophils, metastatic tumors, mucin, amyloid, immunoglobulin, etc.). 5. If the lesion is a growth, is it benign or malignant in appearance? Think of cells in the skin and their associated diseases (keratinocytes, fibroblasts, neurons, adipocytes, melanocytes, histiocytes, pericytes, endothelial cells, smooth muscle cells, follicular cells, sebocytes, eccrine
    [Show full text]
  • Blueprint Genetics Comprehensive Growth Disorders / Skeletal
    Comprehensive Growth Disorders / Skeletal Dysplasias and Disorders Panel Test code: MA4301 Is a 374 gene panel that includes assessment of non-coding variants. This panel covers the majority of the genes listed in the Nosology 2015 (PMID: 26394607) and all genes in our Malformation category that cause growth retardation, short stature or skeletal dysplasia and is therefore a powerful diagnostic tool. It is ideal for patients suspected to have a syndromic or an isolated growth disorder or a skeletal dysplasia. About Comprehensive Growth Disorders / Skeletal Dysplasias and Disorders This panel covers a broad spectrum of diseases associated with growth retardation, short stature or skeletal dysplasia. Many of these conditions have overlapping features which can make clinical diagnosis a challenge. Genetic diagnostics is therefore the most efficient way to subtype the diseases and enable individualized treatment and management decisions. Moreover, detection of causative mutations establishes the mode of inheritance in the family which is essential for informed genetic counseling. For additional information regarding the conditions tested on this panel, please refer to the National Organization for Rare Disorders and / or GeneReviews. Availability 4 weeks Gene Set Description Genes in the Comprehensive Growth Disorders / Skeletal Dysplasias and Disorders Panel and their clinical significance Gene Associated phenotypes Inheritance ClinVar HGMD ACAN# Spondyloepimetaphyseal dysplasia, aggrecan type, AD/AR 20 56 Spondyloepiphyseal dysplasia, Kimberley
    [Show full text]
  • Mixed Ancestry Analysis of Whole-Genome Sequencing Reveals
    medRxiv preprint doi: https://doi.org/10.1101/2021.08.09.21261801; this version posted August 10, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Mixed ancestry analysis of whole-genome sequencing reveals common, rare, and structural variants associated with posterior urethral valves Melanie MY Chan,1 Omid Sadeghi-Alavijeh,1 Horia C Stanescu,1 Catalin D Voinescu,1 Glenda M Beaman,2,3 Marcin Zaniew,4 Stefanie Weber,5 Alina C Hilger,6,7 William G Newman,2,3 Adrian S Woolf,8,9 John O Connolly,1,10 Dan Wood,10 Alexander Stuckey,11 Athanasios Kousathanas,11 Genomics England Research Consortium,11 Robert Kleta,1,12 Detlef Bockenhauer,1,12 Adam P Levine,1,13 and Daniel P Gale1* 1Department of Renal Medicine, University College London, London, NW3 2PF, UK. 2Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, Manchester, M13 9WL, UK. 3Evolution and Genomic Sciences, School of Biological Sciences, University of Manchester, Manchester, M13 9PL, UK. 4Department of Pediatrics, University of Zielona Góra, 56-417 Zielona Góra, Poland. 5Department of Pediatric Nephrology, University of Marburg, 35037 Marburg, Germany. 6Children’s Hospital, University of Bonn, 53113 Bonn, Germany. 7Institute of Human Genetics, University of Bonn, 53127 Bonn, Germany. 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
    [Show full text]
  • Comparison of Structural and Short Variants Detectedby Linked-Read
    cancers Article Comparison of Structural and Short Variants Detected by Linked-Read and Whole-Exome Sequencing in Multiple Myeloma Ashwini Kumar 1,2 , Sadiksha Adhikari 1,2, Matti Kankainen 2,3,4,5 and Caroline A. Heckman 1,2,* 1 Institute for Molecular Medicine Finland-FIMM, HiLIFE-Helsinki Institute of Life Science, iCAN Digital Cancer Medicine Flagship, University of Helsinki, Tukholmankatu 8, 00290 Helsinki, Finland; ashwini.kumar@helsinki.fi (A.K.); sadiksha.adhikari@helsinki.fi (S.A.) 2 iCAN Digital Precision Cancer Medicine, University of Helsinki, 00014 Helsinki, Finland; matti.kankainen@helsinki.fi 3 Medical and Clinical Genetics, University of Helsinki, Helsinki University Hospital, 00029 Helsinki, Finland 4 Translational Immunology Research Program and Department of Clinical Chemistry, University of Helsinki, 00290 Helsinki, Finland 5 Hematology Research Unit Helsinki, Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, 00290 Helsinki, Finland * Correspondence: caroline.heckman@helsinki.fi; Tel.: +358-29-412-5769 Simple Summary: The wide variety of next-generation sequencing technologies requires thorough evaluation and understanding of their advantages and shortcomings of these different approaches prior to their implementation in a precision medicine setting. Here, we compared the performance of two DNA sequencing methods, whole-exome and linked-read exome sequencing, to detect large Citation: Kumar, A.; Adhikari, S.; structural variants (SVs) and short variants in eight multiple myeloma (MM) patient cases. For three Kankainen, M.; Heckman, C.A. patient cases, matched tumor-normal samples were sequenced with both methods to compare somatic Comparison of Structural and Short SVs and short variants. The methods’ clinical relevance was also evaluated, and their sensitivity Variants Detected by Linked-Read and specificity to detect MM-specific cytogenetic alterations and other short variants were measured.
    [Show full text]
  • How Important Are Structural Variants for Speciation?
    G C A T T A C G G C A T genes Review How Important Are Structural Variants for Speciation? Linyi Zhang 1,*, Radka Reifová 2, Zuzana Halenková 2 and Zachariah Gompert 1 1 Department of Biology, Utah State University, Logan, UT 84322, USA; [email protected] 2 Department of Zoology, Faculty of Science, Charles University, 12800 Prague, Czech Republic; [email protected] (R.R.); [email protected] (Z.H.) * Correspondence: [email protected] Abstract: Understanding the genetic basis of reproductive isolation is a central issue in the study of speciation. Structural variants (SVs); that is, structural changes in DNA, including inversions, translocations, insertions, deletions, and duplications, are common in a broad range of organisms and have been hypothesized to play a central role in speciation. Recent advances in molecular and statistical methods have identified structural variants, especially inversions, underlying ecologically important traits; thus, suggesting these mutations contribute to adaptation. However, the contribu- tion of structural variants to reproductive isolation between species—and the underlying mechanism by which structural variants most often contribute to speciation—remain unclear. Here, we review (i) different mechanisms by which structural variants can generate or maintain reproductive isolation; (ii) patterns expected with these different mechanisms; and (iii) relevant empirical examples of each. We also summarize the available sequencing and bioinformatic methods to detect structural variants. Lastly, we suggest empirical approaches and new research directions to help obtain a more complete assessment of the role of structural variants in speciation. Citation: Zhang, L.; Reifová, R.; Keywords: reproductive isolation; hybridization; suppressed recombination Halenková, Z.; Gompert, Z.
    [Show full text]
  • Structural Variation: the Genome’S Hidden Architecture Monya Baker
    TECHNOLOGY FEATURE Uncovering variants 134 Calling for more algorithms 135 Box 1: Getting a bigger picture 136 Structural variation: the genome’s hidden architecture Monya Baker Next-generation sequencing is uncovering more variants than ever before, but it also faces limitations. The Austrian monk Gregor Mendel may tend to take dip- number of nucleotides, structural varia- have founded the science of genetics, but his loidy as the default. tion accounts for more differences between ideas now limit genomic studies, according to Even microarrays human genomes than the more extensively Jim Lupski, a molecular geneticist at Baylor designed to assess studied single-nucleotide differences. A 2010 College of Medicine in Texas. “Mendelian copy number gen- study estimated that such “non-SNP varia- thinking is to genetics as Newtonian think- erally assume that tion” totaled about 50 megabases per human ing is to physics. We saw a whole new world most individuals genome4. when Einstein came along.” carry exactly two Conditions including autism, schizophre- According to Mendelian principles, indi- copies of any partic- nia and Crohn’s disease have all been associ- viduals inherit exactly two copies of each ular region, which ated with structural variation. And uncov- gene—one from each parent. Genes on sex Next-generation can throw off some ering structural variation will be essential chromosomes have long been recognized as sequencing is revealing calculations. for understanding heterogeneity within exceptions, but genetic deletions and duplica- new variation, but With the excep- tumors, says Jan Korbel, who studies struc- tions also break the rules, and in ways that are it won’t be able to tions of very large tural variation at the European Molecular find everything, much harder to track.
    [Show full text]
  • Neurogenomics Coursework (PDF)
    Course Curriculum for the Interdisciplinary Graduate Certificate in Neurogenomics This list reflects the currently approved course curriculum for the Interdisciplinary Graduate Certificate in Neurogenomics. Students must complete a total of at least 16 units of coursework including at least 4 units from each of three (3) fields; Neurology, Genetics/Genomics, and Bioinformatics/Computational/Data Analysis. Note: Due to overlapping subject matter, the same course may be listed within multiple fields and may be offered through different departments under a different course number. As students may enter this certificate program via different graduate programs, all such overlapping courses are listed here for completeness. Neurology-Related Courses Neuroscience Graduate Courses M201. Cell, Developmental, and Molecular Neurobiology. (6) Lecture, six hours. Fundamental topics concerning cellular, developmental, and molecular neurobiology, including intracellular signaling, cell-cell communication, neurogenesis and migration, synapse formation and elimination, programmed neuronal death, and neurotropic factors. Letter grading. M203. Anatomy of Central Nervous System. (4) (Same as Bioengineering M263.) Lecture, 75 minutes; discussion/laboratory, two hours. Prior to first laboratory meeting, students must complete Bloodborne Pathogens training course through UCLA Environment, Health and Safety. Study of anatomical locations of and relationships between ascending and descending sensory and motor systems from spinal cord to cerebral cortex. Covers
    [Show full text]
  • A Structural Variation Reference for Medical and Population Genetics
    Article A structural variation reference for medical and population genetics https://doi.org/10.1038/s41586-020-2287-8 Ryan L. Collins1,2,3,158, Harrison Brand1,2,4,158, Konrad J. Karczewski1,5, Xuefang Zhao1,2,4, Jessica Alföldi1,5, Laurent C. Francioli1,5,6, Amit V. Khera1,2, Chelsea Lowther1,2,4, Received: 2 March 2019 Laura D. Gauthier1,7, Harold Wang1,2, Nicholas A. Watts1,5, Matthew Solomonson1,5, Accepted: 31 March 2020 Anne O’Donnell-Luria1,5, Alexander Baumann7, Ruchi Munshi7, Mark Walker1,7, Christopher W. Whelan7, Yongqing Huang7, Ted Brookings7, Ted Sharpe7, Matthew R. Stone1,2, Published online: 27 May 2020 Elise Valkanas1,2,3, Jack Fu1,2,4, Grace Tiao1,5, Kristen M. Laricchia1,5, Valentin Ruano-Rubio7, Open access Christine Stevens1, Namrata Gupta1, Caroline Cusick1, Lauren Margolin1, Genome Aggregation Database Production Team*, Genome Aggregation Database Consortium*, Check for updates Kent D. Taylor8, Henry J. Lin8, Stephen S. Rich9, Wendy S. Post10, Yii-Der Ida Chen8, Jerome I. Rotter8, Chad Nusbaum1,155, Anthony Philippakis7, Eric Lander1,11,12, Stacey Gabriel1, Benjamin M. Neale1,2,5,13, Sekar Kathiresan1,2,6,14, Mark J. Daly1,2,5,13, Eric Banks7, Daniel G. MacArthur1,2,5,6,156,157 & Michael E. Talkowski1,2,4,13 ✉ Structural variants (SVs) rearrange large segments of DNA1 and can have profound consequences in evolution and human disease2,3. As national biobanks, disease-association studies, and clinical genetic testing have grown increasingly reliant on genome sequencing, population references such as the Genome Aggregation Database (gnomAD)4 have become integral in the interpretation of single-nucleotide variants (SNVs)5.
    [Show full text]
  • Revealing the Impact of Structural Variants in Multiple Myeloma
    RESEARCH ARTICLE Revealing the Impact of Structural Variants in Multiple Myeloma Even H. Rustad1, Venkata D. Yellapantula1, Dominik Glodzik2, Kylee H. Maclachlan1, Benjamin Diamond1, Eileen M. Boyle3, Cody Ashby4, Patrick Blaney3, Gunes Gundem2, Malin Hultcrantz1, Daniel Leongamornlert5, Nicos Angelopoulos5,6, Luca Agnelli7, Daniel Auclair8, Yanming Zhang9, Ahmet Dogan10, Niccolò Bolli11,12, Elli Papaemmanuil2, Kenneth C. Anderson13, Philippe Moreau14, Hervé Avet-Loiseau15, Nikhil C. Munshi13,16, Jonathan J. Keats17, Peter J. Campbell5, Gareth J. Morgan3, Ola Landgren1, and Francesco Maura1 Downloaded from https://bloodcancerdiscov.aacrjournals.org by guest on September 24, 2021. Copyright 2020 American Copyright 2020 by AssociationAmerican for Association Cancer Research. for Cancer Research. ABSTRACT The landscape of structural variants (SV) in multiple myeloma remains poorly understood. Here, we performed comprehensive analysis of SVs in a large cohort of 752 patients with multiple myeloma by low-coverage long-insert whole-genome sequencing. We identified 68 SV hotspots involving 17 new candidate driver genes, including the therapeutic targets BCMA (TNFRSF17), SLAM7, and MCL1. Catastrophic complex rearrangements termed chromothripsis were present in 24% of patients and independently associated with poor clinical outcomes. Templated insertions were the second most frequent complex event (19%), mostly involved in super-enhancer hijacking and activation of oncogenes such as CCND1 and MYC. Importantly, in 31% of patients, two or more seemingly independent putative driver events were caused by a single structural event, dem- onstrating that the complex genomic landscape of multiple myeloma can be acquired through few key events during tumor evolutionary history. Overall, this study reveals the critical role of SVs in multiple myeloma pathogenesis.
    [Show full text]
  • Mapping and Characterization of Structural Variation in 17,795 Human Genomes
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Nature. Manuscript Author Author manuscript; Manuscript Author available in PMC 2020 November 27. Published in final edited form as: Nature. 2020 July ; 583(7814): 83–89. doi:10.1038/s41586-020-2371-0. Mapping and characterization of structural variation in 17,795 human genomes Haley J. Abel1,2,*, David E. Larson1,2,*, Allison A. Regier1,14, Colby Chiang1, Indraniel Das1, Krishna L. Kanchi1, Ryan M. Layer3,4, Benjamin M. Neale5,6,7, William J. Salerno8, Catherine Reeves9, Steven Buyske10, NHGRI Centers for Common Disease Genomics‡, Tara C. Matise11, Donna M. Muzny8, Michael C. Zody9, Eric S. Lander5,12,13, Susan K. Dutcher1,2, Nathan O. Stitziel1,2,14, Ira M. Hall1,2,14,† 1McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO, USA 2Department of Genetics, Washington University School of Medicine, St. Louis, MO, USA 3BioFrontiers Institute, University of Colorado, Boulder, CO, USA 4Department of Computer Science, University of Colorado, Boulder, CO, USA 5Broad Institute of MIT and Harvard, Cambridge, MA, USA 6Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA 7Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA 8Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA 9New York Genome Center, New York, NY, USA 10Department of Statistics, Rutgers University, Piscataway, NJ, USA 11Department of Genetics, Rutgers University, Piscataway, NJ, USA Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms †to whom correspondence should be addressed.
    [Show full text]